The newly approved therapy, called AMX0035, is designed to slow the disease by protecting nerve cells in the brain and spinal cord destroyed by ALS.
FDA approves first ALS drug in 5 years after pleas from patients
The newly approved therapy, called AMX0035, is designed to slow the disease by protecting nerve cells in the brain and spinal cord destroyed by ALS.